Patients should be informed of the possibility of iris color change. In addition,patients who are expected to receive treatment in only one eye should be informed about the potential for increased brown pigmentation of the iris, periorbital tissue,and eyelashes in the treated eye and thus, heterochromia between the eyes.
They should be advised of the potential for a disparity between the eyes in length,thickness, and/or number of eyelashes.Typically the brown pigmentation around the pupil is expected to spread concentrically towards the periphery in affected eyes, but the entire iris or parts of it may also become more brownish. Until more information about increased brown pigmentation is available, patients should be examined regularly and, depending on the clinical situation, treatment may be stopped if increased pigmentation ensues.
The increase in brown iris pigment is not expected to progress further upon discontinuation of treatment, but the resultant color change may be permanent.Neither nevi nor freckles of the iris are expected to be affected by treatment.There is the potential for hair growth to occur in areas where LUMIGAN RC? (bimatoprost ophthalmic solution 0.01% w/v) comes repeatedly in contact with the skin surface. Thus, it is important to apply LUMIGAN RC? as instructed and to avoid it running onto the cheek or other skin areas.